Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In February, we spoke with Jan G. Smith, CEO of Circius Pharma. Jan has over 40 years of experience… read more
Every month, EUCOPE spotlights a member company and the great work they’re doing to drive healthcare innovation in Europe to serve patients better. In February, we spoke with Peter Martin, Director of Norgine BV. Peter Martin has worked in the pharmaceutical industry in Europe and… read more
On our latest Sounds of Science Podcast, we discuss upcoming developments in the field of rare diseases, a timely matter as Rare Disease Day approaches on 28 February. Rare disease is a topic which is very close to the heart of our organisation, as almost… read more
EUCOPE’s Alexander Natz discusses the need for a holistic, integrated, and well-functioning EU environment to foster innovation and re-invest in R&D during the EURONEWS Debates. Rare diseases pose a significant challenge to the European health institutions. Due to the relative irregularity that people suffer from… read more
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) launched a pilot to support the repurposing of medicines. The pilot is being carried out as a follow-up to the European Commission’s Expert Group on Safe and Timely Access to Medicines for Patients… read more
EUCOPE, in partnership with Sanofi, participated in the European Health Forum Gastein 2021 (EHFG) on 29 September in a session on rare diseases to discuss what is needed to stimulate basic research, clinical development, and access to care across the EU in light of the… read more
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
As proven by the fight against COVID-19, data and digital health have the potential to drive change and improve efficiency and accessibility in healthcare. To make the most of this enormous potential, the European Commission opened a public consultation on the European Health Data Space,… read more
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
The multidisciplinary European Expert Group on Orphan Drug Incentives (OD Expert Group) has developed fourteen innovative proposals along the entire lifecycle of orphan drug development to address the unmet needs in rare diseases. With over ninety percent of patients without a centrally approved treatment option,… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View